Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42

Core Viewpoint - Hemostemix Inc. has been granted the trademark "KNOW YOUR HEALTH" in Japan, enhancing its intellectual property and global branding strategy in regenerative medicine and personalized health innovation [2][3]. Trademark Grant Details - The trademark registration covers Classes 1, 5, and 42, which include chemicals for scientific research, pharmaceutical preparations, and technological services in regenerative medicine [6]. - The registration number is International Registration No. 1744775, issued by the Japanese Patent Office [6]. Strategic Significance - The trademark aligns with Hemostemix's clinical programs, particularly the ACP-01 treatment for various ischemic and cardiopulmonary diseases, reinforcing the synergy between brand identity and product pipeline [5]. - The registration strengthens Hemostemix's global intellectual property portfolio, particularly in Japan, a leading market for medical research [10]. - The trademark allows for expanded therapeutic coverage, reflecting Hemostemix's leadership in developing autologous cell-based treatments for vascular and degenerative disorders [10]. - It provides a platform for global collaboration, enabling licensing and commercialization of innovations within Japan's regulatory framework for regenerative medicine [10]. CEO Commentary - The CEO expressed honor at the trademark grant, highlighting its importance for the company's commitment to improving patient health through autologous stem-cell therapy and enhancing partnerships with institutions in Asia [7]. Company Overview - Hemostemix is an autologous stem cell therapy platform company founded in 2003, known for its VesCell™ (ACP-01) treatment, which has shown significant clinical results in various studies [8]. - The company has completed seven clinical studies involving 318 subjects, demonstrating the safety and efficacy of ACP-01 for treating multiple ischemic conditions [8].